The developments are directed towards providing improved treatment options for individuals with Alzheimer’s disease.

Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a ...

CEO Brian Niccol asks Starbucks workers to come back to the office—or he’ll pay them to leave Tropical rainstorm expected to ...

Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPrecli ...

Acumen priced its shares at $16 apiece, the top end of the projected $14 to $16 per share price range. The Charlottesville, Virginia-based company was able to boost the size of the deal, offering ...

Acumen Pharmaceuticals, Inc. INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, completed enrollment in February 2023 ...

Acumen Pharmaceuticals, Inc. Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of 2023 ...

Acumen, the pioneering patient capital impact investment firm, is spinning off its method for measuring impact into a separate for-profit enterprise, 60 Decibels.

I asked Poulsen about Acumen and why the owner selected Atlas Peak, which is situated northeast of the town of Napa Valley, east of Yountville and above the foothills of the Stags Leap District ...

But Acumen’s focus then, and still today to a large extent, is not on earning those financial returns, but on improving the lives of very low-income people in developing countries. ...